Table 1.
Summary of response in 9 men with mCRPC
| # | DOT | FDG category | Metabolic Response 18F-NaF- PET/CT SUVmax | Metabolic Response 18F-NaF- PET/CT SUVavg | Metabolic Response 18F-FDG- PET/CT SUVmax | Metabolic Response 18F-FDG- PET/CT SUVavg | Anatomic Response RECIST 1.1 after 8 weeks therapy | PCWG2 at time of last visit | TTP Based on clinical & radiologic findings |
|---|---|---|---|---|---|---|---|---|---|
| 1 | 285 | Non-avid | PR | SD | Non-avid | Non-avid | Non-measurable | SD | Clinical PD after 285 DOT |
| 2 | 225 | Non-avid | PR | PR | Non-avid | Non-avid | Non-measurable | SD | Suspected PD after 225 DOT determined to be non-oncologic on follow-up |
| 3 | 742+ | Oligometastatic disease | PR | PR | PR | N/A | Non-measurable | SD | Still on trial (DOT 742+) |
| 4 | 53 | Widespread disease | PD | PD | PD | PD | PD | SD | Clinical & imaging PD after 53 DOT |
| 5 | 532 | Non-avid | SD | SD | Non-avid | Non-avid | Non-measurable | SD | Clinical PD after 532 DOT |
| 6 | 231 | Oligometastatic disease | SD | SD | PD | N/A | Non-measurable | SD | Clinical PD after 231 DOT |
| 7 | 563+ | Non-avid | PR | PR | Non-avid | Non-avid | Non-measurable | SD | Still on trial (DOT 563+) |
| 8 | 76 | Widespread disease | PR | PR | PD | PD | SD | SD | Clinical PD after 76 DOT |
| 9 | 516+ | Non-avid | PR | PR | Non-avid | Non-avid | PR | PR | Still on trial (DOT 516+) |
DOT = days on trial, TTP = time to progression, PR = partial response, SD = stable disease, PD = progressive disease.